Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT00003415 Completed - Leukemia Clinical Trials

Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome

Start date: September 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus topotecan in treating patients with myelodysplastic syndrome.

NCT ID: NCT00003407 Withdrawn - Leukemia Clinical Trials

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Start date: February 13, 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine and high-dose combination chemotherapy in treating patients with acute myeloid leukemia or chronic myelogenous leukemia.

NCT ID: NCT00003398 Completed - Lymphoma Clinical Trials

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Start date: September 1998
Phase: Phase 4
Study type: Interventional

RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Phase IV trial to study the incidence of graft-versus-host disease in patients who have hematologic cancer and who are undergoing bone marrow transplantation from a donor.

NCT ID: NCT00003396 Completed - Lymphoma Clinical Trials

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Start date: September 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation from related donors to prevent graft-versus-host disease in treating patients with hematologic cancer.

NCT ID: NCT00003361 Completed - Leukemia Clinical Trials

Decitabine in Treating Patients With Myelodysplastic Syndrome

Start date: April 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of decitabine in treating patients with myelodysplastic syndrome.

NCT ID: NCT00003270 Completed - Lymphoma Clinical Trials

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Start date: September 4, 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy, radiation therapy, and umbilical cord blood transplantation in treating patients with hematologic cancer.

NCT ID: NCT00003171 Completed - Leukemia Clinical Trials

Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome

Start date: May 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with myelodysplastic syndrome.

NCT ID: NCT00003138 Completed - Anemia Clinical Trials

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Start date: March 4, 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Erythropoietin and colony-stimulating factors such as filgrastim stimulate the production of blood cells. It is not yet known whether erythropoietin with or without filgrastim is more effective than standard blood transfusions in reducing the need for transfusions in patients who have anemia associated with myelodysplastic syndrome. PURPOSE: Randomized phase III trial to compare the effectiveness of erythropoietin with or without filgrastim with that of standard blood transfusions in reducing the need for transfusions in patients who have anemia associated with myelodysplastic syndrome.

NCT ID: NCT00003123 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

Start date: August 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Amifostine may be effective in helping blood counts return to normal in treating patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with advanced myelodysplastic syndrome.

NCT ID: NCT00003048 Completed - Clinical trials for Myelodysplastic Syndromes

Amifostine in Treating Patients With Myelodysplastic Syndrome

Start date: June 5, 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.